Renexxion - Ireland
  • Home
  • Company
    • Our Vision
    • Our Leadership Team
  • ​Naronapride (ATI-7505)
    • About Naronapride (ATI-7505)
    • Mechanism of Action
    • Development Status
    • Chemistry and Manufacturing
    • Regulatory Developments
  • Knowledge Centre
    • Gastrointestinal Dysmotility in Cystic Fibrosis (CF)
    • Gastroparesis
    • Chronic Idiopathic Constipation
    • Irritable Bowel Syndrome
    • ​GERD
    • Functional Dyspepsia
  • News
    • Press >
      • Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
      • Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
      • Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders
      • Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
  • Contact

Development Status

More than 900 subjects have been treated with naronapride in clinical trials, including three Phase-2 trials, where naronapride showed efficacy in both lower and upper GI indications.

A Thorough QT (TQT) study testing the cardiac safety of naronapride has also been completed. The results confirmed the cardiac safety profile of naronapride at both therapeutic and supra-therapeutic doses.

Renexxion Ireland has entered into a Licensing and Collaboration Agreement with Dr Falk Pharma GmbH to jointly develop and commercialise Naronapride in Greater Europe, Russia, Central Asian Republics and parts of Australasia. This partnership will commence with Phase 2 development for the initial indication, gastroparesis.  (More...)
 
With a vision of becoming a leading GI biopharmaceutical company globally, our agreement with Dr Falk Pharma will serve as an important catalyst in future worldwide development of Naronapride, including across Greater China, the United States and Japan. We plan to engage with pharmaceutical companies in these regions to explore potential future licensing and collaboration partnerships.

​Renexxion Ireland is committed to ongoing research and development in Ireland, forming a key part of the company’s strategy to lead the way in the GI biopharmaceutical space.
Privacy Policy & Terms of Use
Copyright RENEXXION IRELAND LTD  2023.  All rights reserved.
  • Home
  • Company
    • Our Vision
    • Our Leadership Team
  • ​Naronapride (ATI-7505)
    • About Naronapride (ATI-7505)
    • Mechanism of Action
    • Development Status
    • Chemistry and Manufacturing
    • Regulatory Developments
  • Knowledge Centre
    • Gastrointestinal Dysmotility in Cystic Fibrosis (CF)
    • Gastroparesis
    • Chronic Idiopathic Constipation
    • Irritable Bowel Syndrome
    • ​GERD
    • Functional Dyspepsia
  • News
    • Press >
      • Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
      • Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
      • Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders
      • Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
  • Contact